Hematopoietic Progenitor Cell Products Derived From Bone Marrow and Peripheral Blood

Hematopoietic progenitor cell (HPC) products contain hematopoietic stem cells (HSCs) and HPCs and are used to reconstitute a recipient's bone marrow during hematopoietic stem cell transplantation (HSCT). HPCs collected from bone marrow (HPC, Marrow) and peripheral blood by apheresis (HPC, Apheresis) are discussed. HSC and HPC are identified by the cell surface antigen CD34 and enumeration of CD34+ cells is an indicator of the product's potency. HPC, Apheresis and HPC, Marrow are the primary sources of HSCs for adult and pediatric recipients, respectively. Each product has advantages and disadvantages to be considered for product selection. Compared with HPC, Marrow, HPC, Apheresis is easier to collect, engrafts more quickly reducing peri-transplant morbidity and mortality, contains more lymphocytes resulting in greater graft versus tumor effects and also a greater risk of graft versus host disease, and contains fewer red blood cells reducing the risk of hemolytic reactions when donor and recipient are ABO incompatible.